NasdaqGM:ZLABBiotechs
What Zai Lab (ZLAB)'s Q3 Results and Reaffirmed 2025 Guidance Mean for Shareholders
Zai Lab recently presented at the Morgan Stanley 24th Asia-Pacific Summit in Singapore and announced its Q3 2025 results, highlighting progress in multiple pipeline and commercial programs, including new trial data and ongoing adoption of key therapies in China.
A standout insight from the update is management's reaffirmation of full-year 2025 revenue guidance of at least US$460 million, signaling continued operational discipline and confidence in advancing both commercial and late-stage...